Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Baicalein decreases side population proportion via inhibition of ABCG2 in multiple myeloma cell line RPMI 8226 in vitro.

Gu YY, Liu LP, Qin J, Zhang M, Chen Y, Wang D, Li Z, Tang JZ, Mo SL.

Fitoterapia. 2014 Apr;94:21-8. doi: 10.1016/j.fitote.2014.01.019. Epub 2014 Jan 25.

PMID:
24468191
2.

Scutellaria extract decreases the proportion of side population cells in a myeloma cell line by down-regulating the expression of ABCG2 protein.

Lin MG, Liu LP, Li CY, Zhang M, Chen Y, Qin J, Gu YY, Li Z, Wu XL, Mo SL.

Asian Pac J Cancer Prev. 2013;14(12):7179-86.

3.

Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.

To KK, Poon DC, Wei Y, Wang F, Lin G, Fu LW.

Biochem Pharmacol. 2015 Sep 1;97(1):27-37. doi: 10.1016/j.bcp.2015.06.034. Epub 2015 Jul 20.

PMID:
26206183
4.

Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.

Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM.

Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1022-7.

PMID:
17938326
5.

Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.

Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.

Cancer Lett. 2009 Jun 28;279(1):74-83. doi: 10.1016/j.canlet.2009.01.027. Epub 2009 Feb 18.

PMID:
19232821
6.

Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.

Sato H, Siddig S, Uzu M, Suzuki S, Nomura Y, Kashiba T, Gushimiyagi K, Sekine Y, Uehara T, Arano Y, Yamaura K, Ueno K.

Eur J Pharmacol. 2015 Jan 5;746:258-66. doi: 10.1016/j.ejphar.2014.11.021. Epub 2014 Nov 29.

PMID:
25455500
7.

Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.

Ji N, Yuan J, Liu J, Tian S.

Acta Biochim Biophys Sin (Shanghai). 2010 Dec;42(12):854-62. doi: 10.1093/abbs/gmq097.

PMID:
21106767
8.

C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.

Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG.

Biochem Pharmacol. 2007 Jun 30;74(1):41-53. Epub 2007 Apr 1.

PMID:
17481587
9.

ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.

Shishido Y, Ueno S, Yamazaki R, Nagaoka M, Matsuzaki T.

Anticancer Res. 2013 Apr;33(4):1379-86.

PMID:
23564776
10.

Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.

Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S.

Mol Cancer Ther. 2010 Aug;9(8):2365-76. doi: 10.1158/1535-7163.MCT-10-0108. Epub 2010 Aug 3.

12.

Abnormal Wnt signaling and overexpression of ABCG2 contributes to drug efflux properties of side population cells in nasopharyngeal carcinoma.

Guan GF, Zhang DJ, Zheng Y, Wen LJ, Yu DJ, Lu YQ, Zhao Y.

Mol Med Rep. 2015 Sep;12(3):4352-7. doi: 10.3892/mmr.2015.3935. Epub 2015 Jun 16.

PMID:
26081022
13.

Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors.

Ikegame A, Ozaki S, Tsuji D, Harada T, Fujii S, Nakamura S, Miki H, Nakano A, Kagawa K, Takeuchi K, Abe M, Watanabe K, Hiasa M, Kimura N, Kikuchi Y, Sakamoto A, Habu K, Endo M, Itoh K, Yamada-Okabe H, Matsumoto T.

Leukemia. 2012 Sep;26(9):2124-34. doi: 10.1038/leu.2012.78. Epub 2012 Mar 20.

PMID:
22430632
14.

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.

Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499. Erratum in: Cancer Res. 2008 Dec 15;68(24):10387.

15.

Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation.

Niu Q, Wang W, Li Y, Ruden DM, Wang F, Li Y, Wang F, Song J, Zheng K.

PLoS One. 2012;7(7):e41035. doi: 10.1371/journal.pone.0041035. Epub 2012 Jul 23.

16.

The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.

Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, Cowan K.

Clin Cancer Res. 2002 Jan;8(1):22-8.

17.

The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.

Natarajan K, Bhullar J, Shukla S, Burcu M, Chen ZS, Ambudkar SV, Baer MR.

Biochem Pharmacol. 2013 Feb 15;85(4):514-24. doi: 10.1016/j.bcp.2012.12.006. Epub 2012 Dec 19.

18.

Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug.

Selbo PK, Weyergang A, Eng MS, Bostad M, Mælandsmo GM, Høgset A, Berg K.

J Control Release. 2012 Apr 30;159(2):197-203. doi: 10.1016/j.jconrel.2012.02.003. Epub 2012 Feb 10.

PMID:
22349185
19.

The role of breast cancer resistance protein in acute lymphoblastic leukemia.

Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE, Scheffer GL, Scheper RJ, Vellenga E, de Vries EG.

Clin Cancer Res. 2003 Nov 1;9(14):5171-7.

20.

Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).

Sim HM, Lee CY, Ee PL, Go ML.

Eur J Pharm Sci. 2008 Nov 15;35(4):293-306. doi: 10.1016/j.ejps.2008.07.008. Epub 2008 Aug 3.

PMID:
18725288

Supplemental Content

Support Center